×
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
S&P 500   3,825.33 (+1.06%)
DOW   31,097.26 (+1.05%)
QQQ   282.13 (+0.66%)
AAPL   138.93 (+1.62%)
MSFT   259.58 (+1.07%)
META   160.03 (-0.76%)
GOOGL   2,174.75 (-0.21%)
AMZN   109.56 (+3.15%)
TSLA   681.79 (+1.24%)
NVDA   145.23 (-4.20%)
NIO   21.36 (-1.66%)
BABA   116.00 (+2.04%)
AMD   73.67 (-3.66%)
MU   53.65 (-2.95%)
CGC   2.81 (-1.40%)
T   21.31 (+1.67%)
GE   63.54 (-0.20%)
F   11.32 (+1.71%)
DIS   96.14 (+1.84%)
AMC   13.53 (-0.15%)
PFE   52.31 (-0.23%)
PYPL   71.40 (+2.23%)
NFLX   179.95 (+2.91%)
NYSE:ABBV

AbbVie Stock Forecast, Price & News

$153.80
+0.64 (+0.42%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$151.46
$153.86
50-Day Range
$137.62
$157.62
52-Week Range
$105.56
$175.91
Volume
4.57 million shs
Average Volume
7.56 million shs
Market Capitalization
$271.78 billion
P/E Ratio
22.07
Dividend Yield
3.68%
Price Target
$159.75

AbbVie Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
3.9% Upside
$159.75 Price Target
Short Interest
Healthy
0.92% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.76mentions of AbbVie in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$70.61 M Sold Last Quarter
Proj. Earnings Growth
-15.41%
From $14.02 to $11.86 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.22 out of 5 stars

Medical Sector

19th out of 1,429 stocks

Pharmaceutical Preparations Industry

5th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

AbbVie logo

About AbbVie (NYSE:ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV Stock News Headlines

Is AbbVie About To Get A New Blockbuster Drug?
AbbVie Inc. (ABBV) To Go Ex-Dividend on July 14th
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Company Calendar

Ex-Dividend for 5/16 Dividend
4/13/2022
Last Earnings
4/29/2022
Dividend Payable
5/16/2022
Today
7/01/2022
Ex-Dividend for 8/15 Dividend
7/14/2022
Next Earnings (Estimated)
7/29/2022
Dividend Payable
8/15/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$159.75
High Stock Price Forecast
$200.00
Low Stock Price Forecast
$135.00
Forecasted Upside/Downside
+3.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.5625
Research Coverage
16 Analysts

Profitability

Net Income
$11.54 billion
Pretax Margin
24.77%

Debt

Sales & Book Value

Annual Sales
$56.20 billion
Cash Flow
$17.84 per share
Book Value
$8.73 per share

Miscellaneous

Outstanding Shares
1,767,110,000
Free Float
1,765,696,000
Market Cap
$271.78 billion
Optionable
Optionable
Beta
0.83

Social Links















AbbVie Frequently Asked Questions

Should I buy or sell AbbVie stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AbbVie stock.
View analyst ratings for AbbVie
or view top-rated stocks.

What is AbbVie's stock price forecast for 2022?

16 brokers have issued 1-year price targets for AbbVie's stock. Their ABBV stock forecasts range from $135.00 to $200.00. On average, they predict AbbVie's stock price to reach $159.75 in the next year. This suggests a possible upside of 3.9% from the stock's current price.
View analysts' price targets for AbbVie
or view top-rated stocks among Wall Street analysts.

How has AbbVie's stock performed in 2022?

AbbVie's stock was trading at $135.40 on January 1st, 2022. Since then, ABBV stock has increased by 13.6% and is now trading at $153.80.
View the best growth stocks for 2022 here
.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 29th 2022.
View our earnings forecast for AbbVie
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings results on Friday, April, 29th. The company reported $3.16 earnings per share for the quarter, beating the consensus estimate of $3.15 by $0.01. The business earned $13.36 billion during the quarter, compared to analysts' expectations of $13.61 billion. AbbVie had a trailing twelve-month return on equity of 159.31% and a net margin of 22.00%. AbbVie's revenue for the quarter was up 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.95 earnings per share.
View AbbVie's earnings history
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Thursday, June 23rd. Stockholders of record on Friday, July 15th will be paid a dividend of $1.41 per share on Monday, August 15th. This represents a $5.64 annualized dividend and a dividend yield of 3.67%. The ex-dividend date of this dividend is Thursday, July 14th.
View AbbVie's dividend history
.

Is AbbVie a good dividend stock?

AbbVie(NYSE:ABBV) pays an annual dividend of $5.64 per share and currently has a dividend yield of 3.68%. AbbVie has been increasing its dividend for 50 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of AbbVie is 80.92%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, AbbVie will have a dividend payout ratio of 47.55% next year. This indicates that AbbVie will be able to sustain or increase its dividend.
View AbbVie's dividend history.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $13.92-$14.12 for the period, compared to the consensus earnings per share estimate of $14.11. The company issued revenue guidance of $59.40 billion-$59.40 billion, compared to the consensus revenue estimate of $60.04 billion.

Who are AbbVie's key executives?

AbbVie's management team includes the following people:

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie CEO Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among AbbVie's employees.

What other stocks do shareholders of AbbVie own?

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional investors include Park National Corp OH (0.00%) and Stonebridge Capital Management Inc. (0.00%). Company insiders that own AbbVie stock include Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Edward J Rapp, Elaine K Sorg, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Timothy J Richmond and Timothy J Richmond.
View institutional ownership trends for AbbVie
.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, and Stonebridge Capital Management Inc.. Company insiders that have sold AbbVie company stock in the last two years include Brian L Durkin, Carlos Alban, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
or view top insider-selling stocks.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $153.80.

How much money does AbbVie make?

AbbVie (NYSE:ABBV) has a market capitalization of $271.78 billion and generates $56.20 billion in revenue each year. The company earns $11.54 billion in net income (profit) each year or $6.97 on an earnings per share basis.

How many employees does AbbVie have?

AbbVie employs 50,000 workers across the globe.

Does AbbVie have any subsidiaries?

The following companies are subsidiares of AbbVie: AbbVie (Gibraltar) Holdings Limited, AbbVie (Gibraltar) Holdings Limited Luxembourg S.C.S., AbbVie (Gibraltar) Limited, AbbVie (Pty) Ltd., AbbVie A/S, AbbVie AB, AbbVie AG, AbbVie AS, AbbVie Australasia Holdings Limited, AbbVie B.V., AbbVie Bahamas Ltd., AbbVie Biofarmacevtska družba d.o.o., AbbVie Biopharmaceuticals GmbH, AbbVie Biopharmaceuticals LLC, AbbVie Biopharmaceuticals Ltd., AbbVie Bioresearch Center Inc., AbbVie Biotech Ventures Inc., AbbVie Biotechnology GmbH, AbbVie Biotechnology Ltd, AbbVie Biotherapeutics Inc., AbbVie Biotherapeutics Limited, AbbVie Central Finance B.V., AbbVie Corp, AbbVie Corporation, AbbVie Deutschland GmbH & Co. KG, AbbVie EOOD, AbbVie Endocrine Inc., AbbVie Endocrinology Inc., AbbVie Farmacéuticos S.A. de C.V., AbbVie Farmacêutica Ltda., AbbVie Finance B.V., AbbVie Finance Corporation, AbbVie Finance LLC, AbbVie GK, AbbVie GmbH, AbbVie Holdings Corporation, AbbVie Holdings Inc., AbbVie Holdings KK, AbbVie Holdings SAS, AbbVie Holdings Unlimited, AbbVie Holdings s.r.o., AbbVie International S.à r.l., AbbVie Investments Limited, AbbVie Investments S.à r.l., AbbVie Ireland Holdings Limited, AbbVie Ireland NL B.V., AbbVie Ireland Unlimited Company, AbbVie Japan Holdings B.V., AbbVie Kft., AbbVie Komplementär GmbH, AbbVie L.L.C., AbbVie L.da, AbbVie Limited, AbbVie Limited Liability Company, AbbVie Logistics B.V., AbbVie Ltd, AbbVie Ltd., AbbVie Manufacturing Management Limited, AbbVie Nederland Holdings B.V., AbbVie Operations Singapore Pte. Ltd., AbbVie Overseas S.à r.l., AbbVie Oy, AbbVie Participações Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. z o.o., AbbVie Productos Farmacéuticos Limitada, AbbVie Products LLC, AbbVie Promoção L.da, AbbVie Pte. Ltd., AbbVie Pty Ltd, AbbVie Purchasing LLC, AbbVie Real Estate Management GmbH, AbbVie Research B.V., AbbVie Resources Inc., AbbVie Resources International Inc., AbbVie Respiratory LLC, AbbVie S. de R.L., AbbVie S.A., AbbVie S.A., AbbVie S.A.S., AbbVie S.R.L., AbbVie S.r.l., AbbVie S.à r.l., AbbVie SA, AbbVie SAS, AbbVie SIA, AbbVie Sarl, AbbVie Sdn. Bhd., AbbVie Sp. z o.o., AbbVie Spain S.L., AbbVie Stemcentrx LLC, AbbVie Trading S.R.L., AbbVie Trustee Company Limited, AbbVie Tıbbi İlaçlar Sanayi ve Ticaret Limited Şirketi, AbbVie UAB, AbbVie UK Biopharmaceuticals Ltd, AbbVie UK Holdco Limited, AbbVie UK Ltd, AbbVie US Holdings LLC, AbbVie US LLC, AbbVie Venezuela B.V., AbbVie Venezuela Holdings B.V., AbbVie Ventures LLC, AbbVie d.o.o., AbbVie s.r.o., Aeropharm Technology LLC, Allergan, BioDisplay Technologies Inc., Fournier Laboratories Ireland Ltd., Fremont Holding L.L.C., Fundación AbbVie, IEP Pharmaceutical Devices LLC, ImmuVen, KOS Pharmaceuticals Inc., Knoll LLC, Knoll Pharmaceutical Company, Life Properties Inc., Mavupharma, Organics L.L.C., Pharmacyclics (Europe) Limited, Pharmacyclics (Shanghai) Management Consulting Services Limited, Pharmacyclics Cayman Ltd., Pharmacyclics Inc, Pharmacyclics LLC, Pharmacyclics Switzerland GmbH, Rowell Laboratories Inc., S.C. AbbVie S.R.L., Sapphire Merger Sub Inc., Stem CentRx, Stemcentrx Cayman Ltd., Suffolk Merger Sub Inc., and Unimed Pharmaceuticals LLC.
Read More

When was AbbVie founded?

AbbVie was founded in 2013.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The official website for AbbVie is www.abbvie.com. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049.

This page (NYSE:ABBV) was last updated on 7/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.